

Luca Malorni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4453231/publications.pdf>

Version: 2024-02-01

92
papers

2,475
citations

236925

25
h-index

206112

48
g-index

93
all docs

93
docs citations

93
times ranked

3945
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	2.8	8
2	Abstract P5-13-13: <i>PIK3CA</i> mutations co-occurring with copy number gain identify patients with adverse outcome and potentially different treatment sensitivity among hormone receptor positive and HER2 negative metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P5-13-13-P5-13-13.	0.9	0
3	Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioaltaLEE trial. <i>Cancer Research</i> , 2022, 82, GS3-07-GS3-07.	0.9	5
4	<i>PIK3CA</i> co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 24.	5.2	9
5	Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioaltaEE trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1012-1012.	1.6	3
6	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136.	7.7	25
7	Abstract OT-28-02: Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive / HER2-positive breast cancer - The TOUCH trial. , 2021, , .		0
8	Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial. , 2021, , .		4
9	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4870-4882.	7.0	49
10	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. <i>Breast Cancer Research</i> , 2021, 23, 38.	5.0	14
11	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4687.	4.1	23
12	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2640.	3.7	8
13	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. <i>Cancers</i> , 2021, 13, 2762.	3.7	14
14	292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioaltaLEE trial. <i>Annals of Oncology</i> , 2021, 32, S492.	1.2	3
15	Charting differentially methylated regions in cancer with Rocker-meth. <i>Communications Biology</i> , 2021, 4, 1249.	4.4	7
16	Exploring Serum NMR-Based Metabolomic Fingerprint of Colorectal Cancer Patients: Effects of Surgery and Possible Associations with Cancer Relapse. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 11120.	2.5	3
17	Cell-Free DNA-Methylation-Based Methods and Applications in Oncology. <i>Biomolecules</i> , 2020, 10, 1677.	4.0	31
18	Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. <i>British Journal of Cancer</i> , 2020, 123, 176-177.	6.4	4

#	ARTICLE	IF	CITATIONS
19	Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib+. Cells, 2020, 9, 668.	4.1	23
20	11P BioItaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC). Annals of Oncology, 2020, 31, S20.	1.2	1
21	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. Clinical Cancer Research, 2020, 26, 2783-2788.	7.0	27
22	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TReEnd Trial. Clinical Cancer Research, 2020, 26, 2131-2139.	7.0	40
23	Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer. , 2020, , .		2
24	Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046). , 2020, , .		5
25	Palbociclib added to ongoing endocrine therapy for hormone receptorâ€‘positive HER2â€‘negative metastatic breast cancer: A case report series. Molecular and Clinical Oncology, 2020, 12, 456-460.	1.0	1
26	Abstract P4-04-07: A DNA-methylation signature to predict resistance to the CDK4/6 inhibitor palbociclib. , 2020, , .		0
27	Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance. Biomarkers in Medicine, 2020, 14, 495-498.	1.4	3
28	Abstract P5-06-11: Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC). , 2020, , .		0
29	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Frontiers in Oncology, 2019, 9, 666.	2.8	113
30	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. Cancer Treatment Reviews, 2019, 74, 29-34.	7.7	23
31	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, 392-398.	2.4	12
32	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReEnd trial. Breast Cancer Research, 2019, 21, 71.	5.0	19
33	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptorâ€‘positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFFECT). European Journal of Cancer, 2019, 114, 55-66.	2.8	30
34	The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. Cancers, 2019, 11, 1894.	3.7	53
35	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989160.	3.2	3
36	Abstract 2471: Pan-cancer catalog of Differentially Methylated Regions by Rocker-meth, a new computational method. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TREnd trial. , 2019, , .		0
38	Abstract 3012: Single-cell transcriptomic characterization of luminal breast cancer cell lines with acquired resistance to the CDK4/6 inhibitor palbociclib. , 2019, , .		0
39	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. <i>Breast</i> , 2018, 38, 144-149.	2.2	10
40	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 329-341.	2.5	17
41	ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data. <i>BMC Genomics</i> , 2018, 19, 960.	2.8	22
42	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881559.	3.2	5
43	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 38.	5.2	78
44	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. <i>Anticancer Research</i> , 2018, 38, 4839-4845.	1.1	5
45	Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. <i>Oncotarget</i> , 2018, 9, 16389-16399.	1.8	37
46	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	3.2	14
47	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. <i>Annals of Oncology</i> , 2018, 29, 1748-1754.	1.2	76
48	Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12031-12031.	1.6	1
49	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. <i>Journal of Clinical Oncology</i> , 2018, 36, 570-570.	1.6	0
50	Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?. <i>Oncotarget</i> , 2018, 9, 34031-34032.	1.8	0
51	Targeting the CDK4/6 Pathway in Breast Cancer. , 2017, , 807-817.		0
52	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. <i>Breast Care</i> , 2017, 12, 304-308.	1.4	53
53	Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer. <i>Breast Care</i> , 2017, 12, 288-289.	1.4	1
54	Metabolomic analysis as a tool to identify breast cancer (BC) cell lines resistant to palbociclib (PD). <i>Annals of Oncology</i> , 2017, 28, i17.	1.2	0

#	ARTICLE	IF	CITATIONS
55	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2 ^{âˆ’}) metastatic breast cancer (mBC) (TREnd trial).. Journal of Clinical Oncology, 2017, 35, 1002-1002.	1.6	14
56	Abstract P1-09-13: A RB-1 loss-of-function gene-signature (RBSig) predicts resistance to neoadjuvant chemotherapy in HER2+/ER+ breast cancer patients. , 2017, , .		0
57	Abstract P6-02-07: Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib. , 2017, , .		0
58	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor ^{âˆ’} Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5755-5764.	7.0	20
59	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research, 2016, 14, 470-481.	3.4	39
60	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget, 2016, 7, 68012-68022.	1.8	110
61	Low hormone receptor (HR) status and the benefit of hormonal therapy (HT) in patients with early breast cancer (EBC). Annals of Oncology, 2015, 26, iii15.	1.2	0
62	A multifactorial ^{âˆ’} Consensus Signature ^{âˆ™} by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. Npj Breast Cancer, 2015, 1, 15003.	5.2	3
63	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 541-552.	27.6	121
64	Heterogeneity of <i>PIK3CA</i> mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Molecular Oncology, 2015, 9, 749-757.	4.6	146
65	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Medicine, 2015, 13, 46.	5.5	27
66	New approaches for improving outcomes in breast cancer in Europe. Breast, 2015, 24, 321-330.	2.2	42
67	Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant. , 2015, , .		0
68	AhR (Aryl Hydrocarbon Receptor) Polymorphisms: A Possible Role in TCDD (Dioxins)-AhR Binding and Carcinogenesis. International Journal of Biology, 2014, 6, .	0.2	5
69	Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?. Cancers, 2014, 6, 684-707.	3.7	28
70	Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial. Annals of Oncology, 2014, 25, i8.	1.2	1
71	Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Current Opinion in Oncology, 2014, 26, 568-575.	2.4	33
72	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2014, 106, djt337-djt337.	6.3	218

#	ARTICLE	IF	CITATIONS
73	In silico analysis of a multifactorial consensus signature (ConSig) for predicting response to anthracycline (A)-based neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 1025-1025.	1.6	1
74	The continued evidence from overviews: What is the clinical utility?. Breast, 2013, 22, S8-S11.	2.2	1
75	Adjuvant Chemotherapy: Which Patient? What Regimen?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 3-8.	3.8	5
76	Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse) Tj ETQq0 0 0 rgBT /Overlock 3 0 Tf 50 6		
77	Adjuvant Chemotherapy: Which Patient? What Regimen?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 3-8.	3.8	2
78	Polyendocrine Treatment in Estrogen Receptor-Positive Breast Cancer: A Fact Yet to Be Proven. Journal of Clinical Oncology, 2012, 30, 1897-1900.	1.6	10
79	Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Research and Treatment, 2012, 136, 795-804.	2.5	175
80	Introduction: Luminal A and B: How Curable are they?. Annals of Oncology, 2012, 23, ix27.	1.2	0
81	S07 Overcoming resistance to endocrine therapies: Multiple interventions to reach the goal. Breast, 2011, 20, S4.	2.2	0
82	P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer.. , 2011, , .		0
83	Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Research and Treatment, 2010, 123, 651-660.	2.5	21
84	PCN138 HEALTH-CARE COSTS ASSOCIATED WITH BREAST CANCER MANAGEMENT. Value in Health, 2010, 13, A278.	0.3	0
85	Triple-negative breast cancers: Biomarkers and outcomes.. Journal of Clinical Oncology, 2010, 28, 10621-10621.	1.6	1
86	Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. Journal of Experimental and Clinical Cancer Research, 2009, 28, 135.	8.6	16
87	Vandetanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (HER1), Potentiates Anti-Tumor Effects of Combined Endocrine and Trastuzumab Treatment in Estrogen Receptor-Positive (ER+)/HER2-Overexpressing Xenografts.. , 2009, , .		0
88	Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts. Cancer Research, 2008, 68, 7493-7501.	0.9	120
89	RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors. Oncogene, 2005, 24, 6303-6313.	5.9	30
90	A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer. Clinical Cancer Research, 2005, 11, 4741-4748.	7.0	312

#	ARTICLE	IF	CITATIONS
91	Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. <i>Annals of Oncology</i> , 2005, 16, iv7-iv13.	1.2	41
92	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. <i>Oncogene</i> , 2003, 22, 246-255.	5.9	46